来源：环球网 脑肿瘤是全球性的治疗难题，传统的手术治疗即便手术成功切除了肿瘤，也难免造成神经损伤或脑水肿 等继发性创伤。大部分药物因难以逾越血脑屏障，也无法达到治疗效果。而脑肿瘤的发生率近年来不断 走高，尤其是脑转移瘤的发生率。据悉，我国仅脑转移瘤年发病人数就超过150万。 北大医疗集团党委书记、董事长朱友刚表示，此次战略合作不仅是双方的新起点，更是医疗服务创新和 产业化探索上的前瞻实践。北京大学国际医院作为平安集团线下未来发展的旗舰，是集团战略投资的重 点方向。期待以此次合作为突破口，未来在肿瘤尤其是脑肿瘤治疗领域，携手打造国内领先的诊疗能 力；更希望以此为契机，在更多关键领域开启新合作，共同构建科技领先、服务领先、患者体验优良的 医疗模式，在共同发展中推动医疗健康事业进步。 10月23日，北京大学国际医院与百洋医药签署战略合作协议，共建精准放疗中心。该中心即将落地北京 大学国际医院，依托百洋医药运营的ZAP-X火星舟放射外科机器人，打造以脑肿瘤"专病专治"为核心的 高水平放疗平台，通过优化脑肿瘤精准放疗场景，为数百万脑肿瘤患者提供创新放疗解决方案。 ...

Group 1: Public Health Response - The 2025 version of the Chikungunya fever diagnosis and treatment plan has been released to enhance the standardized treatment level across various medical institutions in China [1] - The release reflects China's heightened vigilance towards imported infectious diseases, as there is currently no vaccine available for the virus [1] Group 2: Company Control Changes - Renfu Pharmaceutical announced a change in its actual controller to China Merchants Group, following the completion of board restructuring and control acquisition [2] - This change is expected to stabilize the company's governance structure and promote resource integration [2] Group 3: Drug Development and Approvals - Huahai Pharmaceutical's HB0043, a dual-target antibody drug, has received clinical trial approval, marking it as the first of its kind targeting IL-17A and IL-36R [3][4] - CS231295 from Microchip Biotech has received FDA approval for clinical trials, showcasing its potential in treating brain tumors due to its ability to penetrate the blood-brain barrier [4] - Shuyou Shen has obtained a summary report for BDB-001 injection, demonstrating significant clinical advantages in reducing steroid dosage for ANCA-associated vasculitis [5]

Group 1 - The National Health Commission and the National Administration of Traditional Chinese Medicine released the 2025 version of the Chikungunya fever diagnosis and treatment plan to enhance standardized treatment levels [1] - The new treatment plan reflects China's heightened vigilance towards imported infectious diseases, as there is currently no vaccine available for the virus [1] Group 2 - Renfu Pharmaceutical announced a change in its actual controller to China Merchants Group, with China Merchants Biomedical controlling approximately 4.34 billion shares, accounting for 26.62% of the total share capital [2] - The change in control is expected to stabilize the company's governance structure and promote resource integration [2] Group 3 - Huahai Pharmaceutical's HB0043, the world's first dual-target antibody drug targeting IL-17A and IL-36R, has received clinical trial approval from the National Medical Products Administration [3] - HB0043 shows stronger efficacy than monoclonal antibodies in various animal disease models, indicating its potential for treating autoimmune diseases [3] Group 4 - Microchip Biotech received FDA approval for the clinical trial of CS231295, a selective AuroraB inhibitor for treating advanced solid tumors, highlighting its ability to penetrate the blood-brain barrier [4] - The approval signifies a differentiated innovation capability in the field of brain tumor treatment, where most drugs struggle to cross the blood-brain barrier [4] Group 5 - Shutaishen obtained a summary report for the I/II phase clinical study of BDB-001 injection for ANCA-associated vasculitis, showing significant clinical advantages in steroid reduction and complete remission rates [5] - The company plans to advance to phase III clinical trials to further validate the clinical benefits for AAV patients [5]